Sanofi Loses Injunction Bid In Generic Eloxatin Spat

By Melissa Lipman

Law360, New York (March 10, 2010, 7:12 PM ET) -- A federal judge has again denied Sanofi-Aventis US LLC's request for a preliminary injunction against Fresenius Kabi Pharma Ltd., one of the last remaining defendants in the pharmaceutical giant's battle to keep generic versions of popular colon cancer drug Eloxatin off the market.

Judge Joel Pisano of the U.S. District Court for the District of New Jersey on Tuesday rejected Sanofi's renewed motion for an injunction against Fresenius without expanding on his reasons.

At Tuesday's hearing, the judge said only that he didn't think Sanofi had...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles